Breaking News, Collaborations & Alliances, Trials & Filings

AGC Biologics Inks TCR-T Cell Services Agreement with Medigene

AGC will provide autologous production for a next-generation-therapy product focused on the treatment of solid cancers.

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), entered into a new service agreement with Medigene AG. Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials. With the product currently in the pre-clinical phase, AGC Biologics will perform a process transfer and clinical manufacturing of Medig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters